|Table of Contents|

Research progress of nuclear export protein inhibitors in the treatment of hematological tumors

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 08
Page:
1553-1558
Research Field:
Publishing date:

Info

Title:
Research progress of nuclear export protein inhibitors in the treatment of hematological tumors
Author(s):
GAO Zhongjie; MA Liangming
Deparment of Hematology,the Third Hospital of Shanxi Medical University(Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences，Tongji Shanxi Hospital)，Shanxi Taiyuan 030032,China.
Keywords:
nuclear export protein; hematologic tumors; gene mutation; drug resistance
PACS:
R732.2
DOI:
10.3969/j.issn.1672-4992.2024.08.033
Abstract:
Nuclear export proteins are important proteins in nucleocytoplasmic transport.Nuclear export protein 1 (XPO1) mediates the transport of various tumor suppressor proteins,including p53,as well as cell cycle regulatory proteins.Inhibition of XPO1 transport function can affect cell proliferation,differentiation,apoptosis and other processes to achieve anti-tumor purposes.In this paper,we review the research of nuclear export protein inhibitors in common gene mutations and drug resistance of some commonly used anti-tumor drugs in hematological tumors,and discuss the application of nuclear export protein inhibitors in hematological tumors and more fields.

References:

［1］MARRETTA AL,DI LORENZO G,RIBERA D,et al.Selinexor and the selective inhibition of nuclear export:A new perspective on the treatment of sarcomas and other solid and non-solid tumors［J］.Pharmaceutics,2021,13(9):1522.
［2］WESTIN SN,FU S,TSIMBERIDOU A,et al.Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors:Results of an open label,single-center,multi-arm phase 1b study with expansion phase in ovarian cancer［J］.Gynecol Oncol,2023,168:76-82.
［3］JANS DA,MARTIN AJ,WAGSTAFF KM.Inhibitors of nuclear transport［J］.Curr Opin Cell Biol,2019,58:50-60.
［4］AZMI AS,UDDIN MH,MOHAMMAD RM.The nuclear export protein XPO1-from biology to targeted therapy［J］.Nat Rev Clin Oncol,2021,18(3):152-169.
［5］MO CC,JAGANNATH S,CHARI A,et al.Selinexor for the treatment of patients with previously treated multiple myeloma［J］.Expert Rev Hematol,2021,14(8):697-706.
［6］RICHARD S,JAGANNATH S.Targeting nuclear export proteins in multiple myeloma therapy［J］.BioDrugs,2022,36(1):13-25.
［7］苏铮,刘连奇,李微.第二代XP01抑制剂-eltanexor［J］.临床药物治疗杂志,2019,17(08):1-4. SU Z,LIU LQ,LI W.Eltanexor-the second generation XPO1 inhibitor［J］.Clinical Medication Journal,2019,17(08):1-4.
［8］LIAO Y,KE X,DENG T,et al.The second-generation XPO1 inhibitor eltanexor inhibits human cytomegalovirus (HCMV) replication and promotes type I interferon response［J］.Front Microbiol,2021,12:675112.
［9］张甲辉,王亮.XPO1抑制剂在血液系统恶性肿瘤中的研究进展［J］.中国癌症防治杂志,2020,12(05):578-584. ZHANG JH,WANG L.Research progress of XPO1 inhibitors in hematological malignancies［J］.Chinese Journal of Oncology Prevention and Treatment,2020,12(05):578-584.
［10］VICENTE ATS,SALVADOR JAR.MDM2-based proteolysis-targeting chimeras (PROTACs):An innovative drug strategy for cancer treatment［J］.Int J Mol Sci,2022,23(19):11068.
［11］BALASUBRAMANIAN SK,AZMI AS,MACIEJEWSKI J.Selective inhibition of nuclear export:a promising approach in the shifting treatment paradigms for hematological neoplasms［J］.Leukemia,2022,36(3):601-612.
［12］GUO Y,LIU Z,DUAN L,et al.Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation［J］.Invest New Drugs,2022,40(4):738-746.
［13］FALINI B,BRUNETTI L,SPORTOLETTI P,et al.NPM1-mutated acute myeloid leukemia:from bench to bedside［J］.Blood,2020,136(15):1707-1721.
［14］SHARMA N,LIESVELD JL.NPM 1 mutations in AML-the landscape in 2023［J］.Cancers (Basel),2023,15(4):1177.
［15］GARZON R,SAVONA M,BAZ R,et al.A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia［J］.Blood,2017,129(24):3165-3174.
［16］FIEDLER W,CHROMIK J,AMBERG S,et al.A phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia［J］.Br J Haematol,2020,190(3):e169-e173.
［17］KLOSSOWSKI S,MIAO H,KEMPINSKA K,et al.Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia［J］.J Clin Invest,2020,130(2):981-997.
［18］LIU Y,AZIZIAN NG,DOU Y,et al.Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma［J］.J Hematol Oncol,2019,12(1):119.
［19］YU H,WU S,LIU S,et al.Venetoclax enhances DNA damage induced by XPO1 inhibitors:A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia［J］.J Cell Mol Med,2022,26(9):2646-2657.
［20］GANDHI UH,SENAPEDIS W,BALOGLU E,et al.Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma［J］.Clin Lymphoma Myeloma Leuk,2018,18(5):335-345.
［21］TOTIGER TM,CHAUDHRY S,MUSI E,et al.Protein biomarkers for response to XPO1 inhibition in haematologic malignancies［J］.J Cell Mol Med,2023,27(4):587-590.
［22］FISHER MA,FRIEDLANDER SY,ARRATE MP,et al.Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies［J］.Blood Adv,2020,4(3):586-598.
［23］ TONG WH,SCHOONES JW.Association of FLT3-ITD length with overall survival in acute myeloid leukemia:a systematic review and meta-analysis［J］.Haematologica,2023,108(3):926-927.
［24］BORLENGHI E,CATTANEO C,BERTOLI D,et al.Prognostic relevance of NPM1 and FLT3 mutations in acute myeloid leukaemia,longterm follow-up-a single center experience［J］.Cancers (Basel),2022,14(19):4716.
［25］BRINTON LT,SHER S,WILLIAMS K,et al.Cotargeting of XPO1 enhances the antileukemic activity of midostaurin and gilteritinib in acute myeloid leukemia［J］.Cancers (Basel),2020,12(6):1574.
［26］TAYLOR J,MI X,PENSON AV,et al.Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents:a single-centre,single-arm,phase 2 trial［J］.Lancet Haematol,2020,7(8):e566-e574.
［27］BHATNAGAR B,ZHAO Q,MIMS AS,et al.Selinexor in combination with decitabine in patients with acute myeloid leukemia:results from a phase 1 study［J］.Leuk Lymphoma,2020,61(2):387-396.
［28］LEE S,MOHAN S,KNUPP J,et al.Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents［J］.J Hematol Oncol,2022,15(1):103.
［29］PENG Y,HUANG Z,ZHOU F,et al.Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells［J］.Cell Commun Signal,2021,19(1):71.
［30］LI Q,HUANG Z,PENG Y,et al.RanBP3 regulates proliferation,apoptosis and chemosensitivity of chronic myeloid leukemia cells via mediating SMAD2/3 and ERK1/2 nuclear transport［J］.Front Oncol,2021,11:698410.
［31］DELFORGE M,RADDOUX J,ANTONIS C,et al.Selinexor,bortezomib and dexamethasone:an effective salvage regimen for heavily pretreated myeloma patients［J］.Onco Targets Ther,2022,15:243-250.
［32］DIMA D,JIANG D,SINGH DJ,et al.Multiple myeloma therapy:emerging trends and challenges［J］.Cancers (Basel),2022,14(17):4082.
［33］TRKULIA KL,MANJI F,KURUVILLA J,et al.Nuclear export in non-Hodgkin lymphoma and implications for targeted XPO1 inhibitors［J］.Biomolecules,2023,13(1):111.
［34］SAENZ-PONCE N,PILLAY R,DELONG LM,et al.Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas［J］.Sci Transl Med,2018,10(447):eaar7223.
［35］GALINSKI B,LUXEMBURG M,LANDESMAN Y,et al.XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB［J］.Transl Oncol,2021,14(8):101114.
［36］WALKER JS,HING ZA,HARRINGTON B,et al.Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia［J］.J Hematol Oncol,2021,14(1):17.
［37］NAKHODA S,VISTAROP A,WANG YL.Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma［J］.Br J Haematol,2023,200(2):137-149.
［38］STEPHENS DM,HUANG Y,RUPPERT AS,et al.Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies:A phase I study［J］.Clin Cancer Res,2022,28(15):3242-3247.
［39］SEYMOUR EK,KHAN HY,LI Y,et al.Selinexor in combination with R-CHOP for frontline treatment of non-Hodgkin lymphoma:Results of a phase I study［J］.Clin Cancer Res,2021,27(12):3307-3316.

Memo

Memo:
山西省留学归国人员科研基金（编号：2017-126）
Last Update: 1900-01-01